EUVIMEDEUVIMED entdecken
Leitlinie

Guideline versus clinician recommended duration of dual anti-platelet therapy following acute coronary syndrome (ANZACS-QI 78)

Sophie J Rees, Andrew J Kerr

New Zealand Medical Journal · 2024

DOI: 10.26635/6965.6437 ↗

Kurz gefasst

Leitlinie in der Zeitschrift New Zealand Medical Journal, 2024. Verfasst von Sophie J Rees und 1 weiteren Autor:innen. Beteiligte Einrichtung: House Officer, Te Whatu Ora Counties Manukau, New Zealand. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Dual Anti-Platelet Therapy, Practice Guidelines as Topic, Percutaneous Coronary Intervention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

aim: The recommended duration of dual anti-platelet therapy (DAPT) following acute coronary syndrome (ACS) for patients without atrial fibrillation varies from 1 month to 1 year depending on the balance of risks of ischaemia and major bleeding. Patients on DAPT with a high risk of gastrointestinal bleeding are also recommended to receive a proton pump inhibitor (PPI). Our aim was to audit current practice against the 2020 European Society of Cardiology (ESC) guideline recommendations. methods: One hundred consecutive ACS patients treated with percutaneous coronary intervention discharged from Middlemore Hospital and without atrial fibrillation in the first quarter of 2023 were studied. ANZACS-QI ischaemic (I) and bleeding (B) risk scores were calculated, with patients categorised in four groups based on ESC recommendations—low I/low B risk, low I/high B, high I/low B and high I/high B. Guideline and clinician recommended duration of DAPT and prescription of PPI were compared. results: All patients were planned for DAPT at discharge and 91% a PPI. Up to four out of five ACS patients could have been planned for shorter DAPT durations based on the ESC guideline recommendations. Over half of included patients (53%) had a high bleeding risk, yet 85% of these patients received 12 months of DAPT despite ESC recommendations of 1–3 months. conclusions: There was a divergence between clinical practice and the recommendations of the 2020 ESC guidelines. We discuss these results in relation to the updated August 2023 ESC guidelines, which have reaffirmed a 12-month duration of DAPT as the default position.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeDual Anti-Platelet TherapyPractice Guidelines as TopicPercutaneous Coronary InterventionProton Pump InhibitorsPlatelet Aggregation InhibitorsHumansMaleFemaleAgedMiddle AgedGuideline AdherenceNew ZealandGastrointestinal Hemorrhage

Substanzen

Proton Pump InhibitorsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • House Officer, Te Whatu Ora Counties Manukau, New Zealand.
  • Cardiologist, Te Whatu Ora Counties Manukau; Honorary Professor of Medicine, The University of Auckland, New Zealand.

Zitieren

APA

Rees, S. J., & Kerr, A. J. (2024). Guideline versus clinician recommended duration of dual anti-platelet therapy following acute coronary syndrome (ANZACS-QI 78). New Zealand Medical Journal. https://doi.org/10.26635/6965.6437

Vancouver

Rees SJ, Kerr AJ. Guideline versus clinician recommended duration of dual anti-platelet therapy following acute coronary syndrome (ANZACS-QI 78). New Zealand Medical Journal. 2024. doi:10.26635/6965.6437

BibTeX
@article{Rees2024,
  author = {Rees, Sophie J and Kerr, Andrew J},
  title = {Guideline versus clinician recommended duration of dual anti-platelet therapy following acute coronary syndrome (ANZACS-QI 78)},
  journal = {New Zealand Medical Journal},
  year = {2024},
  doi = {10.26635/6965.6437}
}
Kostenlos starten →